The Clinical Efficacy of a Topical Dorzolamide in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa

The Clinical Efficacy of a Topical Dorzolamide in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy of a Topical Dorzolamide in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005852

Enrollment

Registered

2011-06-27

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinitis pigmentosa

Interventions

1% dorzolamide three times daily in each eye during the follow-up period

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) patients with retinitis pigmentosa (2) BCVA >= 0.1 (3) patinets whose agreement was shown by him/herself

Exclusion criteria

Exclusion criteria: (1) a past history of glaucoma or ocular hypertension (2) patients with another macular disorder, such as epiretinal membrane (3) a past history of using the test drug within 6 months (4) pregnant subjects, subjects suspected of being pregnant, or breast-feeding subjects (5) hypersensitivity to the test drug (6) a past history of the entry into another clinical trial within 1 year (7) inappropriate case judged by investigator or subinvestigators

Design outcomes

Primary

Measure	Time frame
retinal thickness, best-corrected visual acuity, visual field, side effect	—

Countries

Japan

Contacts

Public ContactYasuhiro Ikeda

Kyushu university hospital Department of Ophthalmology

ymocl@pathol1.med.kyushu-u.ac.jp092-642-5648

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026